Literature DB >> 11748651

Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy.

Laurent Andréoletti1, Alexandre Lescieux, Valérie Lambert, Ali Si-Mohamed, Mathieu Matta, Pierre Wattré, Laurent Bélec.   

Abstract

Progressive Multifocal Leukoencephalopathy (PML) is a severe and fatal demyelinating disease that occurs especially in HIV-infected patients. It has been suggested that JC virus (JCV) migrates in peripheral blood leukocytes from the kidney to the central nervous system where it initiates demyelination. To investigate the physiopathological role of the peripheral blood virus in the development of PML, the prevalence of JCV infection and the levels of JCV DNA load were evaluated in peripheral blood leukocytes or mononuclear cells of 10 AIDS patients at the time of onset of PML symptoms, and in 150 non-PML HIV-1-infected patients using a semiquantitative PCR and ELISA-hybridization assay. In PML-AIDS patients, 60% (6/10) were positive for JCV-DNA detection in peripheral blood cells compared with 26% (13/50) and 18% (18/100) positive for non-PML HIV-infected control patients with CD4+ T lymphocyte counts below and above 200.10(6) /l, respectively (60 vs. 26%, P = 0.06; 60 vs. 18%; P = 0.007). The prevalence of JCV infection in the peripheral blood cells taken from controls appeared to be independent of the CDC stage of infection and CD4+ T lymphocyte counts. The predictive positive value of a positive JCV DNA PCR in peripheral blood cells for the diagnosis of PML in an HIV-infected patient was 16% whereas the predictive negative value was 96%. The levels of circulating JCV DNA load, ranging from 1.69 to 2.53 log of copies per 10(6) cells, did not differ between patients at time of PML symptoms onset and controls, and appeared to be independent of the clinical and the biological status in control patients. The findings do not indicate any significant JCV genomic replication activity in peripheral blood cells at the onset of PML disease, and suggest that JCV replication markers in the systemic compartment would not be valuable for predicting the development of PML in AIDS patients. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748651     DOI: 10.1002/jmv.2103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

Review 1.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

2.  BKV-DNA and JCV-DNA co-quantification assay to evaluate viral load in urine and serum.

Authors:  Chiara Merlino; Massimiliano Bergallo; Roberta Daniele; Alessandro Negro Ponzi; Rossana Cavallo
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

3.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 4.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 5.  Natalizumab and progressive multifocal leucoencephalopathy.

Authors:  J R Berger
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

6.  New commercially available PCR and microplate hybridization assay for detection and differentiation of human polyomaviruses JC and BK in cerebrospinal fluid, serum, and urine samples.

Authors:  Hélène Moret; Véronique Brodard; Côme Barranger; Nicolas Jovenin; Martine Joannes; Laurent Andréoletti
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 7.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

8.  Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.

Authors:  Cesare Giovanni Fedele; Maria Rosa Ciardi; Salvatore Delia; Gerardo Contreras; José Luis Perez; Maria De Oña; Elisa Vidal; Antonio Tenorio
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

9.  Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome.

Authors:  Luis Del Valle; Sahnila Enam; Cesar Lara; Judith Miklossy; Kamel Khalili; Jennifer Gordon
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  WU polyomavirus in patients infected with HIV or hepatitis C virus, Connecticut, USA, 2007.

Authors:  Michael A Miller; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.